BioCentury | Dec 17, 2020

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

Philogen immunocytokine for brain cancerUniversity of Zurich and Swiss Federal Institute of Technology Zurich (ETHZ) scientists reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of Philogen S.p.A.’s Fibromun (L19-TNF)...
BioCentury | Sep 1, 2020

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Aug 15, 2020
Product Development

Celltrion launches antigen and serology COVID-19 tests in the U.S., Verily adds capacity with CLIA lab and more

COVID-19 diagnostic developments this week include the addition of two types of COVID-19 rapid test kits by Celltrion and Verily’s move to boost capacity with a new CLIA lab in South San Francisco. ...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | Jul 16, 2020

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

U.K. clears early access to lumasiran The U.K.’s Medicines and Healthcare products Regulatory Agency is making lumasiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) available to patients with primary hyperoxaluria type I before its approval by the...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...
BioCentury | Jun 13, 2020
Product Development

ACTIV coming into focus, starting COVID-19 therapy trials in June

A consortium that is pooling the resources of the U.S. government and global biopharmaceutical companies to discover and develop drugs and vaccines for COVID-19 has selected a first wave of therapies for testing and plans...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
Items per page:
1 - 10 of 938